GSK4381562

Poster: SRF813, a fully human monoclonal antibody targeting the inhibitory receptor CD112R, enhances immune cell activation, and anti-CD112R treatment in vivo demonstrates preclinical antitumor activity

American Association for Cancer Research Annual Meeting, June 2020